Compare EARN & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EARN | DERM |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 190.3M |
| IPO Year | 2012 | 2021 |
| Metric | EARN | DERM |
|---|---|---|
| Price | $4.32 | $7.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.38 | ★ $12.67 |
| AVG Volume (30 Days) | ★ 356.2K | 174.9K |
| Earning Date | 06-16-2026 | 05-13-2026 |
| Dividend Yield | ★ 20.51% | N/A |
| EPS Growth | N/A | ★ 34.72 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $61,858,000.00 |
| Revenue This Year | $7.69 | $39.72 |
| Revenue Next Year | $19.57 | $63.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 10.20 |
| 52 Week Low | $4.25 | $4.31 |
| 52 Week High | $5.77 | $9.56 |
| Indicator | EARN | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 41.40 | 46.58 |
| Support Level | $4.29 | $5.92 |
| Resistance Level | $4.49 | $7.39 |
| Average True Range (ATR) | 0.07 | 0.38 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 2.38 | 4.55 |
Ellington Credit Co The Fund is focused on acquiring and actively managing a portfolio of corporate CLOs, mainly mezzanine debt and equity tranches, which are typically collateralized by portfolios consisting mainly of below-investment-grade senior secured loans with a large number of discrete underlying borrowers across various industry sectors. Additionally, the Fund may also invest in CLO loan accumulation facilities, which are entities that acquire corporate loans and other similar corporate credit-related assets in anticipation of ultimately collateralizing a CLO transaction. The company's primary investment objectives are to generate attractive current income and risk-adjusted total returns for shareholders.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.